Girls treated for Hodgkin's disease during adolescence acquire risk of developing breast cancer

NewsGuard 100/100 Score

Girls treated for Hodgkin's disease during adolescence acquire a considerable risk of developing breast cancer, as shown by an observational study published in the current issue of Deutsches Ärzteblatt International. The study, which was carried out by Günther Schellong and his colleagues in the German Working Group on the Long-Term Sequelae of Hodgkin's Disease, has an unusually long follow-up time (average 17.8 years, maximum 33 years).

The incidence figures for secondary breast cancer are based on long-term observation of 590 female patients in the German-Austrian pediatric treatment trials dating back to the years 1978 to 1995. The authors estimate that 19% of the girls treated with radiotherapy for Hodgkin's disease develop secondary breast cancer within 30 years as a result of that therapy. Because of these findings, a structured screening program for breast cancer in this high-risk group has been set up in Germany, making use of existing structures put in place by the German Consortium for Hereditary Breast and Ovarian Cancer (Deutsches Konsortium für familiären Brust- und Eierstockkrebs).

The study authors recommend that, when supradiaphragmatic radiotherapy is necessary in girls over the age of 9, the part(s) of the chest exposed to the radiation should be kept as small as medically justifiable. This will allow the risk of breast cancer to be kept as low as possible.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New trials show promise for immune checkpoint blockers in early-stage lung cancer